L. De Mattos-Arruda

发表

Clinical implications of intratumor heterogeneity: challenges and opportunities

S. Ramón y. Cajal, J. Hernández-Losa, J. Castellví, 2020, Journal of Molecular Medicine.

Intersect-then-combine approach: improving the performance of somatic variant calling in whole exome sequencing data using multiple aligners and callers

Carlos Caldas, Oscar M. Rueda, Suet-Feung Chin, 2017, Genome Medicine.

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

M. Berger, J. Reis-Filho, L. Norton, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast

O. Mariani, J. Reis-Filho, A. Vincent-Salomon, 2014, Molecular oncology.

Cancer as an ecomolecular disease and a neoplastic consortium.

O. Larsson, S. Ramón y. Cajal, J. Hernández-Losa, 2017, Biochimica et biophysica acta. Reviews on cancer.

Neoantigen prediction and computational perspectives towards clinical benefit: Recommendations from the ESMO Precision Medicine Working Group.

M. Griffith, N. McGranahan, V. Guallar, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer

Edith M. Ross, N. Friedman, F. Markowetz, 2019, Cell reports.

Circulating tumor cells in metastatic breast cancer: the need for a standardized approach.

L. De Mattos-Arruda, H. Azim, I. Elattar, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

The Genomic Landscape of Male Breast Cancers

Melissa P. Murray, C. Hudis, J. Reis-Filho, 2016, Clinical Cancer Research.

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

M. Berger, J. Reis-Filho, L. Norton, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases

J. Reis-Filho, B. Weigelt, P. Nuciforo, 2018, Oncotarget.

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.

J. Lindberg, J. Reis-Filho, M. Diehn, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies

Philippe Bédard, L. Siu, J. Rodon, 2015, British Journal of Cancer.

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.

T. Fehm, C. Caldas, J. Reis-Filho, 2014, The Lancet. Oncology.

Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation

T. Fehm, C. Caldas, S. Dawson, 2022, The oncologist.

Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases.

M. Weller, A. Bardelli, J. Seoane, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Liquid biopsy for HER2-positive breast cancer brain metastasis: the role of the cerebrospinal fluid

L. De Mattos-Arruda, 2017, ESMO Open.

News from ASCO 2018

M. Balic, L. De Mattos-Arruda, S. Gampenrieder, 2018, Breast Care.

Are acinic cell carcinomas of the breast and salivary glands distinct diseases?

Salvatore Piscuoglio, Marcia Edelweiss, Ian O Ellis, 2015, Histopathology.

CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion

C. Criscitiello, M. Preusser, T. Ruhstaller, 2018, ESMO Open.

Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.

X. Puente, J. Baselga, E. Felip, 2013, Cancer discovery.

The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis‐generating study

I. Ellis, J. Reis-Filho, L. Norton, 2015, The Journal of pathology.

Use of Pertuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer

J. Cortés, L. De Mattos-Arruda, 2013, Advances in Therapy.

Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer.

G. Curigliano, M. Vazquez, A. Prat, 2021, European journal of cancer.

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

Salvatore Piscuoglio, Xavier de la Cruz, Jordi Rodon, 2015, Nature Communications.

New emerging targets in cancer immunotherapy: the role of neoantigens

J. Blanco, J. Carrillo, C. Aguilar-Gurrieri, 2020, ESMO Open.

Development of molecular biomarkers in individualized treatment of colorectal cancer.

J. Tabernero, R. Dienstmann, L. De Mattos-Arruda, 2011, Clinical colorectal cancer.

Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases

M. Weller, A. Bardelli, J. Seoane, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

The challenge of intratumour heterogeneity in precision medicine

J. Seoane, L. De Mattos-Arruda, J Seoane, 2014, Journal of internal medicine.

Advances in first-line treatment for patients with HER-2+ metastatic breast cancer.

J. Cortés, L. De Mattos-Arruda, 2012, The oncologist.

Escaping out of the brain.

L. De Mattos-Arruda, J. Seoane, 2014, Cancer discovery.

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

T. Fehm, A. Rademaker, C. Caldas, 2019, Critical reviews in oncology/hematology.

Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection.

L. De Mattos-Arruda, J. Rodón, 2013, The oncologist.

Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing

M. Berger, J. Reis-Filho, B. Weigelt, 2014, Molecular Oncology.

Cell‐free circulating tumour DNA as a liquid biopsy in breast cancer

C. Caldas, L. De Mattos-Arruda, 2016, Molecular oncology.

Management of the axilla in early breast cancer patients in the genomic era.

S. Di Cosimo, I. Rubio, J. Balmaña, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors

R. Rosell, Álvaro González, J. Cortés, 2015, Melanoma research.

PIK3CA mutation inhibition in hormone receptor-positive breast cancer: time has come

L. De Mattos-Arruda, 2020, ESMO Open.

Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer.

J. Tabernero, D. Olmos, L. De Mattos-Arruda, 2011, Future oncology.

Brain metastasis: New opportunities to tackle therapeutic resistance

J. Seoane, L. De Mattos-Arruda, 2014, Molecular oncology.

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

S. Chin, C. Caldas, S. Sammut, 2021, NPJ breast cancer.

Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema

M. Invernizzi, L. De Mattos-Arruda, A. Michelotti, 2020, Frontiers in Oncology.

Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.

M. Piccart, A. Goldhirsch, M. Paesmans, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Progress against solid tumors in danger: the metastatic breast cancer example.

E. Perez, G. Hortobagyi, H. Rugo, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper.

M. Piccart, D. Lacombe, D. Kelly, 2017, European journal of cancer.

How to use liquid biopsies to treat patients with cancer

G. Siravegna, L. De Mattos-Arruda, 2021, ESMO open.

J. Baselga, J. Tabernero, S. Cosimo, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?

J. Cortés, L. De Mattos-Arruda, 2012, Breast.

MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients

E. Giovannetti, G. Calin, P. Nuciforo, 2015, Oncotarget.